Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 9Carcinoma, Non-Small-Cell Lung 5Recurrence 3Neoplasms 3Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Obesity 1Neuroblastoma 1Motor Activity 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Hepatitis 1Health Behavior 1Gliosarcoma 1Glioma 1Fibrosis 1Cognition Disorders 1Child Behavior 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Behavior 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Spermine Synthase × Clear all
NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Lumos Pharma

Phase 1/2 Completed
160 enrolled 21 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡